Listed as part of the S&P 400 Index, the business is a publicly traded company with common stocks available on the NASDAQ under ticker symbol SLXP.
For more than 20 years, the business has been developing, licensing and marketing products that are geared towards the treatment of gastrointestinal disorders. Some of the products they manufacture are FULYZAQ (crofelemer), COLAZAL (blasalazide disodium), GIAZO (balsalazide disodium), AZASAN (azathioprine), CYCLOSET (bromocriptine mesylate) and DEFLUX. The majority of these products are distributed to the largest pharmaceutical market in the world, the United States. Through their specialty sales force, the company is able to reach out and build a franchise in the gastroenterology community.
Salix Pharmaceuticals Ltd also finds mean to weave strategic alliances to market their products outside the country. Through this business strategy they are able to avoid significant cost, infrastructure and risks.